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Purpose: In patients with type 2 diabetes mellitus
(T2DM) not achieving glycemic targets using oral
antidiabetes drugs (OADs), studies suggest that timely
insulin initiation has clinical beneﬁts. Insulin initiation
at the early versus late stage of disease progression has
not been explored in detail. This retrospective data-
base analysis investigated clinical and economic out-
comes associated with the timing of insulin initiation
in patients with T2DM treated with Z1 OAD in a
real-world US setting.
Methods: This study linked data from the Truven
Health MarketScan® Commercial database, Medicare
Supplemental database, and Quintiles Electronic Med-
ical Records database. A total of 1830 patients with
T2DM were included. Patients were grouped accord-
ing to their OAD use before basal insulin initiation
(1, 2, or Z3 OADs) as a proxy for the timing of
insulin initiation. Clinical and economic outcomes
were evaluated over 1 year of follow-up.
Findings: During follow-up the 1 OAD group,
compared with the 2 and Z3 OADs groups, had a
greater reduction in glycosylated hemoglobin A1c
(1.7% vs 1.0% vs 0.9%, respectively; P o
0.0001), greater achievement of glycemic target
(38.2% vs 26.7% vs 19.6%, respectively; P o
0.0001), and a lower incidence of hypoglycemia
(2.7% vs 6.6% vs 5.0%, respectively; P ¼ 0.0002),
with no difference in total health care costs ($21,167
vs $21,060 vs $20,133, respectively).
Implications: This study shows that early insulin
initiation (represented by the 1 OAD group) may be
clinically beneﬁcial to patients with T2DM not
controlled with OADs, without adding to costs.
This supports the call for timely initiation of
individualized insulin therapy in this population.110(Clin Ther. 2016;38:110–121) & 2016 The Authors.
Published by Elsevier HS Journals, Inc.
Key words: early insulinization, economic outcomes,
insulin initiation, type 2 diabetes.INTRODUCTION
After diagnosis of type 2 diabetes mellitus (T2DM),
lifestyle changes and oral antidiabetes drugs (OADs)
are recommended.1 If blood glucose targets are not
achieved with ﬁrst-line therapy after approximately 3
months, guidelines from the American Diabetes Asso-
ciation (ADA) and the European Association for the
Study of Diabetes (EASD) advocate the addition of
another OAD or insulin to the treatment regimen.1
Importantly, the treatment regimen should be tailored
to each patient’s needs. However, because of the
progressive nature of diabetes, most patients will
eventually need insulin therapy to maintain or
achieve glycemic targets (generally glycosylated
hemoglobin A1c [A1C] o7.0%).1,2
Several clinical studies suggest that timely initiation of
insulin therapy is beneﬁcial for patients with diabetes.3–5
However, the differences between initiating insulin when
a patient is unable to control hyperglycemia on an OAD
or at a later stage of a patient’s disease progression when
taking multiple OADs have not been examined fully.
This is important because many patients with T2DM
with inadequate glycemic control using OADs endureVolume 38 Number 1
P. Levin et al.a prolonged glycemic burden before they begin insulin
therapy.6,7 Clinical inertia, the failure to intensify treat-
ment despite a patient not meeting glycemic targets, may
be a contributing factor.8,9 Both patients and physicians
are responsible for clinical inertia: concerns about hypo-
glycemia, weight gain, and injectable agents contribute to
resistance to the initiation of insulin therapy.10 However,
the association between the timing of insulin initiation
and health care outcomes in real-world settings, including
the economic impact, remains to be explored.
This analysis assessed the clinical and economic
outcomes associated with the timing of basal insulin
initiation in US patients with T2DM previously
treated with Z1 OAD.METHODS
Study Design and Patients
This was a retrospective database analysis of com-
bined data from 3 databases: 2 Truven Health Market-
Scan databases (Claims and Encounters [Commercial]
and Medicare Supplemental and Coordination of
Beneﬁts [Medicare]) and the linked Quintiles Electronic
Medical Records (EMR) database. These 3 sources
provided data for patients insured commercially or
through Medicare and information from their EMR.
The MarketScan Commercial database contains the
health care experience of 39.5 million employees and
their dependents, covered under a variety of fee-for-
service and managed-care health plans. The Market-
Scan Medicare database contains the health care
experience of 3.4 million retirees with Medicare
supplemental insurance paid for by employers. Both
the MarketScan Commercial and Medicare databases
provide detailed cost, use, and outcomes data for health
care services performed in the inpatient and outpatient
settings. The Quintiles EMR database contains ambu-
latory clinical data from 49000 providers and covers
413.5 million unique patient lives.
A hybrid deterministic-probabilistic approach was
used to link a subset of patients in the MarketScan
databases to the Quintiles EMR database at the
patient level. The deterministic match required an
exact match on several variables from both sources,
including the 3-digit ZIP code of residence, sex, and
month and year of birth. The probabilistic match
involved ﬁnding exact matches for Z3 physician
visits. Physician visits were selected as the attribute
for matching due to likely agreement between medicalJanuary 2016records and claims data. In total, 1,348,279 patients
were included in the linked MarketScan and Quintiles
database.
Patients included in the study were 18 years of age
or older and received a diagnosis of T2DM between
July 1, 2004 and December 31, 2011. Eligible patients
were deﬁned as having had Z1 inpatient visit or Z2
non-inpatient visits (Z30 days apart) with a primary
or secondary diagnosis of T2DM (International Clas-
siﬁcation of Diseases, Ninth Revision, Clinical Mod-
iﬁcation [ICD-9-CM] diagnosis code 250.x0 or 250.
x2).11 Patients initiated on a basal insulin (neutral
protamine Hagedorn [NPH] insulin, insulin glargine,
or insulin detemir) between July 1, 2004 and
December 31, 2010 (index date) and who were
also receiving Z1 class of OADs (metformin,
sulfonylureas, thiazolidinediones, α-glucosidase inhib-
itors, meglitinides, dipeptidyl peptidase-4 inhibitors)
at baseline were included. Patients were required to
have had continuous health care coverage for 6
months before (baseline) and 12 months after (fol-
low-up) initiation of insulin. Baseline A1C values and
weight measurements were available for all patients.
Patients were excluded from the study if they had
ﬁlled any prescription claims for insulin during the
baseline period other than rapid-acting insulin claims
within 15 days before insulin initiation, which could
be initiated in addition to basal insulin as part of a
basal bolus insulin treatment regimen.
The study population was stratiﬁed by the number
of baseline OADs (1, 2, or Z3) as a proxy for the
timing of insulin initiation relative to diabetes disease
progression. This was based on previous12 and
current1 ADA guidelines on pharmacological therapy
for hyperglycemia in T2DM in which the
recommendation is to start with OAD monotherapy
(metformin or a sulfonylurea), and insulin may be
added to either an OAD or subsequently to a
combination of OADs.
Baseline Measures
Patient demographic and clinical variables com-
prised sex, age, weight, body mass index (BMI),
duration of diabetes, comorbidities, Deyo-modiﬁed
Charlson Comorbidity Index,13 hypoglycemic events,
and A1C values for the 6-month baseline period or 15
days after the index date. If there were multiple
measurements during the baseline period, the value
from the test closest to the index date was used.111
Clinical TherapeuticsHealth care resource utilization was described by
place of service (outpatient ofﬁce visits, emergency
department [ED] visits, and inpatient admissions) for
the 6-month baseline. Diabetes-related health care
resource utilization included claims with a primary
or secondary diagnosis of diabetes (ICD-9-CM diag-
nosis code 250.xx). Health care costs were computed
as total paid amounts of adjudicated claims during the
6-month baseline and were annualized for compara-
bility. Diabetes-related health care costs included costs
from medical claims with a primary or secondary
diagnosis of diabetes (ICD-9-CM diagnosis code 250.
xx), antidiabetes medications, and glucose meters and
test strips. All costs were adjusted to 2011 US dollars
using the medical care component of the US consumer
price index.14
Endpoint Measures
Clinical outcomes were evaluated over 1 year of
follow-up. They included A1C reduction from base-
line and the proportion of patients achieving A1C
o7.0%, and changes in body weight and BMI; values
reported within 3 months of the end of the 12-month
follow-up period were included; if there were multiple
measurements the value from the test closest to the
end of follow-up was used. Hypoglycemia in the
follow-up period was also reported; hypoglycemia
was deﬁned as a health care encounter with a primary
or secondary diagnosis of hypoglycemia (ICD-9-CM
diagnosis codes 251.0, hypoglycemic coma; 251.1,
other speciﬁed hypoglycemia; or 251.2, hypoglycemia,
unspeciﬁed)15 and other relevant codes using an
algorithm developed by Ginde et al.16 The setting of
a hypoglycemic event (outpatient ofﬁce, inpatient
admissions, or ED) was used as a proxy for its
severity. Treatment persistence was deﬁned as a
patient remaining on study drugs during the follow-
up period without discontinuation or switching after
study drug initiation.17 Study medication was
considered discontinued if the prescription was not
reﬁlled within the expected time of medication
coverage (the 90th percentile of the time, stratiﬁed
by the metric quantity supplied, between ﬁrst and
second ﬁlls in patients with Z1 reﬁll).17 Patients who
restarted their initial medication after a period
without it during follow-up were considered non-
persistent.
Health care resource utilization was described by
place of service (outpatient ofﬁce, ED, inpatient112admission) during the 1-year follow-up. Diabetes-
related health care resource utilization included
claims with a primary or secondary diagnosis of
diabetes (ICD-9-CM diagnosis code: 250.xx).
Health care costs were computed as total amounts
of adjudicated claims during the 1-year follow-up.
Diabetes-related health care costs included costs
from medical claims with a primary or secondary
diagnosis of diabetes (ICD-9-CM diagnosis code:
250.xx), antidiabetes medications, and glucose me-
ters and test strips.
Statistical Analysis
Confounding factors are an issue in nearly all
observational research in which patients are not
randomly assigned to treatment cohorts, and, there-
fore, certain patient characteristics may be associated
with both exposure and outcome. Such issues were
addressed using the inverse probability-of-treatment
weighting method,18–21 which adjusts for differences
in baseline characteristics between study cohorts,
rendering groups more comparable. A multinomial
logistic regression model was used to predict the
propensity of timing of insulin initiation (after 1, 2,
or Z3 OADs) given the demographic and clinical
characteristics of the patient; the variables included in
this model were age group, sex, region, urbanicity,
index year, index insulin type (basal or basal plus
short acting), baseline high-density cholesterol, pro-
vider specialty (specialist, primary care, unknown),
duration of diabetes, baseline hypoglycemia, baseline
obesity, baseline depression, baseline cerebrovascular
disease, baseline diabetes-related outpatient ofﬁce
visit, and baseline diabetes-related other outpatient
services. The inverse of the propensity was applied
as the probability weight to outcome measures to
produce weighted results. Baseline results are pre-
sented unweighted, whereas outcomes were weighted
using the inverse probability-of-treatment weighting
method.
Global tests (χ2 tests for categorical variables and
ANOVA for continuous variables) were used to
determine statistically signiﬁcant differences between
the patient groups for unweighted baseline character-
istics and weighted study outcomes. Pairwise statisti-
cal comparisons between the 1, 2, and Z3 OADs
groups were conducted using χ2 tests for categorical
variables and t tests for continuous variables in
unweighted and weighted results.Volume 38 Number 1
Patients with ≥ 1 prescription claim for basal insulina from July 1, 2004 through December 31, 2010
Patients with T2DM diagnosed from July 1, 2004 through December 31, 2011
n = 1830
Patients who initiated basal insulin from July 1, 2004 through December 31, 2010
Patients aged ≥ 18 years at insulin initiation
Patients with continuous enrollment in a health plan with both medical and pharmacy coverage
for 6 months prior to insulin initiation through 12 months after insulin initiation
Patients with ≥ 1 OAD prescription claim during the 6 months prior to insulin initiation
Patients meeting selection criteria
Patients with non-missing weight values during the 6 months prior to and through 15 days after insulin initiation
Patients with non-missing A1C test results during the 6 months prior to and through 15 days
after insulin initiation (included in the study)
N = 26,092
n = 23,794
n = 16,910 
n = 16,688
n = 7561
n = 5572
n = 5572
n = 2540 
Figure 1. Data attrition. *Insulin glargine, insulin detemir, or NPH insulin. A1C ¼ glycosylated hemoglobin
A1c; EMR ¼ electronic medical record; OAD ¼ oral antidiabetes drug; T2DM ¼ type 2 diabetes
mellitus.
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Baseline Patient Characteristics
A total of 1830 eligible patients were included in
the analysis; patient attrition details are shown in
Figure 1. Of the included patients, 24.6% used 1
OAD at baseline, 40.3% used 2 OADs, and 35.1%
usedZ3 OADs (Table I). In the 1 OAD group, 46.0%
of the patients were previously treated with metformin
and 34.4% with a sulfonylurea. In the 2 OADs group,
the most commonly used OADs were metformin
(80.9%), sulfonylureas (74.4%), and thiazolidine-
diones (24.0%). In the Z3 OADs group, the most
commonly used OADs were metformin (95.6%),
sulfonylureas (93.1%), thiazolidinediones (71.3%),
and dipeptidyl peptidase-4 inhibitors (46.3%).January 2016The mean age was 57 years, 47% were female, the
mean A1C was 9.2%, the mean weight was 99.5 kg
with a mean BMI of 34.5 kg/m2, and 3% of patients
had experienced Z1 hypoglycemic event. Table I
shows the baseline clinical and demographic data for
the patients grouped by number of OADs at baseline. In
these unweighted data, there were signiﬁcant differences
between the 2 OADs and Z3 OADs groups compared
with the 1 OAD group for sex (P ¼ 0.008) and
duration of diabetes at insulin initiation (P ¼ 0.002).
Health Care Resource Utilization Outcomes
(Baseline)
At baseline, patients in the 1 OAD group had
signiﬁcantly higher all-cause inpatient admissions113
Table I. Baseline characteristics (all data are unweighted).
1 OAD
(n ¼ 450)
2 OADs
(n ¼ 738)
Z3 OADs
(n ¼ 642) P*
Age, y, mean (SD) 56.7 (13.9) 57.4 (12.1) 57.4 (11.4) 0.550
Female, no. (%) 234 (52.0) 347 (47.0) 273 (42.5) 0.008
Weight, kg, mean (SD) 99.2 (26.3) 98.8 (23.2) 100.4 (22.6) 0.480
BMI, kg/m2, mean (SD) 34.7 (8.9) 34.4 (7.4) 34.3 (7.1) 0.746
A1C, %, mean (SD) 9.3 (2.3) 9.2 (2.0) 9.1 (1.8) 0.146
Duration of diabetes at insulin initiation, no. (%)
o1 years 118 (26.2) 113 (15.3) 117 (18.2) 0.002
1–2 years 7 (1.6) 14 (1.9) 10 (1.6)
3–4 years 3 (0.7) 8 (1.1) 7 (1.1)
Z5 years 4 (0.9) 10 (1.4) 12 (1.9)
Unknown 318 (70.7) 593 (80.4) 496 (77.3)
OADs, no. (%)
Sulfonylureas 155 (34.4) 549 (74.4) 598 (93.1) o0.001
Metformin 207 (46.0) 597 (80.9) 614 (95.6) o0.001
Thiazolidinediones 46 (10.2) 177 (24.0) 458 (71.3) o0.001
α-Glucosidase inhibitors 1 (0.2) 3 (0.4) 22 (3.4) o0.001
Meglitinides 9 (2.0) 32 (4.3) 48 (7.5) 0.001
Dipeptidyl peptidase-4 inhibitors 32 (7.1) 118 (16.0) 297 (46.3) o0.001
Deyo-CCI score,13 mean (SD) 1.9 (1.7) 1.8 (1.7) 1.7 (1.5) 0.051
Comorbid conditions, no. (%)
Retinopathy 11 (2.4) 35 (4.7) 28 (4.4) 0.131
Nephropathy 0 6 (0.8) 4 (0.6) 0.173
Neuropathy 51 (11.3) 62 (8.4) 61 (9.5) 0.247
Hypertension 205 (45.6) 332 (45.0) 269 (41.9) 0.391
Dyslipidemia 137 (30.4) 223 (30.2) 226 (35.2) 0.100
Depression 22 (4.9) 39 (5.3) 36 (5.6) 0.873
Hypoglycemia, no. (%)
Z1 Hypoglycemic event 12 (2.7) 25 (3.4) 18 (2.8) 0.728
All-cause health care utilization, no. (%)
Z1 Inpatient admission 95 (21.1) 133 (18.0) 89 (13.9) 0.006
Z1 ED visit 125 (27.8) 155 (21.0) 119 (18.5) 0.001
Z1 Endocrinologist visit 63 (14.0) 89 (12.1) 106 (16.5) 0.060
Diabetes-related health care utilization, no. (%)
Z1 Inpatient admission 57 (12.7) 93 (12.6) 65 (10.1) 0.284
Z1 ED visit 27 (6.0) 45 (6.1) 38 (5.9) 0.990
A1C ¼ glycosylated hemoglobin A1c; BMI ¼ body mass index; CCI ¼ Charlson Comorbidity Index; ED ¼ emergency
department; OAD ¼ oral antidiabetes drug.
*A χ2 test was used for categorical variables and ANCOVA was used for continuous variables.
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P. Levin et al.(21.1%; P ¼ 0.006) and ED visits (27.8%; P ¼ 0.001)
than those in the 2 and Z3 OADs groups (2 OADs:
18.0% and 21.0%, respectively; andZ3 OADs: 13.9%
and 18.5%, respectively) (Table I). There were no
signiﬁcant differences between the groups for diabetes-
related health care utilization at baseline (Table I).
Health Care Costs (Annualized Baseline)
Total all-cause health care costs differed between
the groups at baseline, with higher costs for the group
treated with 2 OADs than the Z3 OADs group
($23,998 vs $19,517, respectively; P ¼ 0.048), but
there was no signiﬁcant difference between the 1 OAD
and 2 or Z3 OADs groups (Figure 2A). Non-ofﬁce
outpatient costs ($6088 vs $4019, respectively; P ¼
0.008) and outpatient ofﬁce costs ($1173 vs $1044,
respectively; P ¼ 0.012) were higher for the 1 OAD
group versus theZ3 OADs group. Prescription charges
were higher for the Z3 OADs group ($5535) than for
the 1 OAD group ($3363; P o 0.0001) and the 2
OADs group ($3859; P o 0.0001). There were no
other signiﬁcant differences between the groups.
There were no differences in total diabetes-related
health care costs between the groups at baseline
(Figure 2B). However, prescription costs were higher
at baseline for the Z3 OADs group ($2330) compared
with the 1 OAD ($400) and 2 OADs ($909) groups
(P o 0.0001 for both). Baseline outpatient ofﬁce costs
were also higher for theZ3 OADs group ($473) versus
the 1 OAD ($395) and 2 OADs ($413) groups (P ¼
0.0007 and P ¼ 0.003, respectively). There were no
other differences between the groups.
Clinical Outcomes and Treatment Persistence
(1-Year Follow-Up)
Weighted results show that, at follow-up, com-
pared with the 2 OADs and Z3 OADs groups, the 1
OAD group had a signiﬁcantly greater reduction in
A1C, a higher proportion of patients achieving A1C
o7.0%, and fewer patients experiencing Z1 hypo-
glycemic event (Table II).
Treatment persistence was signiﬁcantly lower in the
1 OAD group than in the other 2 groups (51.8% vs
58.0% for the 2 OADs group [P ¼ 0.004] and 68.7%
for the Z3 OADs group [P o 0.001]). There was no
signiﬁcant difference in the duration of persistence
between the groups.
Stratiﬁed by baseline BMI, the greatest reductions
in A1C were among patients in the 1 OAD groupJanuary 2016when baseline BMI wasr30 kg/m2 or 31 to 35 kg/m2
(P o 0.01) (Figure 3). Among patients who were
severely obese at baseline (BMI 435 kg/m2), there
were no signiﬁcant differences in A1C outcome at
follow-up between treatment groups. The weight-
adjusted daily average consumption of insulin per
100 lb of bodyweight did not differ in the BMI
r30 kg/m2 strata (15, 14, and 15 U for the 1, 2,
and Z3 OADs groups, respectively) or in the BMI 31
to 35 kg/m2 strata (12, 13, and 13 U, respectively); in
the BMI 435 kg/m2 strata, it was signiﬁcantly lower
in the 1 OAD group (11 U) compared with the Z3
OADs group (14 U) (P ¼ 0.0036), but not the 2
OADs group (12 U). No signiﬁcant differences were
observed for change in weight (þ1.2 kg vs þ1.6 kg vs
þ1.0 kg) or BMI (þ0.5 kg/m2 vs þ0.6 kg/m2 vs þ
0.4 kg/m2) between the 1 OAD, 2 OADs, and Z3
OADs groups, respectively.
Health Care Resource Utilization Outcomes
(1-Year Follow-Up)
Weighted results show that, during follow-up, a
signiﬁcantly higher proportion of patients in the 1
OAD group had all-cause inpatient admissions
(26.1%) compared with the 2 OADs (20.0%; P o
0.001) and Z3 OADs (13.0%; P o 0.0001) groups.
The proportion of patients with all-cause ED visits
was similar across the 3 groups (26.2%, 27.7%, and
24.1%, respectively). A signiﬁcantly lower propor-
tion of patients in the 1 OAD group had diabetes-
related outpatient ofﬁce visits (87.9%) compared
with the 2 OADs group (94.1%) and the Z3 OADs
group (93.4%) (P o 0.0001 for both). A signiﬁcantly
higher proportion of patients in the Z3 OADs group
(95.5%) compared with patients in the 1 OAD group
(91.1%; P ¼ 0.0001) and 2 OADs group (92.7%; P ¼
0.0072) had Z1 diabetes supply claim.
Health Care Costs (1-Year Follow-Up)
Weighted results show that during follow-up, there
were no differences in medical costs between the OAD
groups. Prescription costs were higher in the Z3
OADs group ($6754) compared with the 1 OAD
($4838) and 2 OADs ($5715) groups (P o 0.0001
and P ¼ 0.0072, respectively) (Figure 2A).
At follow-up, the overall diabetes-related health
care costs were similar, but with higher prescription
costs for the Z3 OADs group ($3121) compared
with the 1 OAD ($1759) and 2 OADs ($2090) groups115
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Clinical Therapeutics(P o 0.0001 for both) (Figure 2B). Outpatient ofﬁce
visit costs were also higher in the Z3 OADs group
compared with the 1 OAD group ($483 vs $385;
P ¼ 0.0015).116DISCUSSION
In this real-world observational study, initiating basal
insulin therapy in patients previously treated with 1
OAD resulted in greater A1C reductions and a lowerVolume 38 Number 1
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Figure 3. Change in glycosylated hemoglobin A1c
from baseline to 1-year follow-up strati-
fied by baseline BMI. A1c ¼ glycosylated
hemoglobin A1c; BMI ¼ body mass
index; OAD ¼ oral antidiabetes drug.
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January 2016risk of hypoglycemia than adding insulin to treatment
with Z2 OADs. The greater use of sulfonylureas and
thiazolidinediones in the 2 and Z3 OADs groups
indicates that, in this study, those who did not
intensify treatment with insulin, intensiﬁed it with
sulfonylureas and thiazolidinediones as the disease
progressed. Risks of hypoglycemia and weight gain
are the main disadvantages associated with the use of
all insulins,1 and concerns about these issues are one
of the key barriers to insulin initiation.10 Of note,
therefore, were the comparatively lower rates of
hypoglycemia among patients previously treated
with 1 OAD than with Z2 OADs. Lower hypo-
glycemia in the 1 OAD group after insulin initiation
could be related to the shorter duration of diabetes in
this group, resulting in patients less prone to
hypoglycemia22 or possibly with less hypoglycemia
unawareness because of better glucose counter-
regulation and less autonomic neuropathy.23 How-
ever, baseline neuropathy and nephropathy were not
signiﬁcantly different between the groups, suggesting
that this was not the case in this population.
Alternatively, the 2 and Z3 OADs groups had a
greater sulfonylurea use at baseline. This may partly
explain the higher incidence of hypoglycemia because
sulfonylurea use has been linked with hypo-
glycemia.1,24 The difﬁculty in titrating sulfonylurea117
Clinical Therapeuticsdose may explain lower hypoglycemia in the 1 OAD
group (where sulfonylurea use is less common) as
providers can respond to the threat of hypoglycemia
by reducing insulin by a few units, whereas sulfony-
lurea dosing does not have such ﬂexibility because of
fewer dose choices.
After initiation of insulin treatment, patients in the
1 OAD group were more likely to achieve A1C
o7.0% with no increase in hypoglycemic events.
Conversely, in the 2 and Z3 OADs groups, a lower
proportion of patients achieved A1C o7.0%, yet
hypoglycemic events nearly doubled. This suggests
that early insulin initiation could reduce unnecessary
initiation of sulfonylureas and the higher resultant rate
of hypoglycemic events, as seen in those patients on
multiple OAD regimens who then add insulin.
The clinical beneﬁts associated with early initiation
of insulin were achieved despite the 1 OAD group
having the lowest treatment persistence rate. The 1-
year persistence rates (ranging from 52% to 69%)
compare favorably with other analyses of basal insulin
initiation after OAD treatment in real-world US
settings, which range between 44% and 80%.25–29
According to ADA and EASD guidelines, patient-
centered approaches to T2DM treatment should con-
sider age, weight, and comorbidities.1 As 80% of
patients with T2DM are overweight or obese, key
outcomes were stratiﬁed by baseline BMI. In severely
obese patients (BMI 435 kg/m2), efﬁcacy was not
improved by the early addition of insulin. Those with
1 OAD had lower daily average consumption than
those in the Z3 OADs group. Although greater
insulin resistance among more obese patients may be
the cause of this ﬁnding, obese and leaner patients
have been shown to have similar islet dysfunction.30
More research is required to clarify the underlying
reason for this ﬁnding.31–33 Together with our results,
these data highlight the need for more personalized
approaches to the treatment of patients with T2DM,
incorporating factors such as weight and their effect
on treatment outcomes.
Although we compared early or late initiation of
insulin (using the number of OADs as a proxy for the
timing of initiation relative to disease progression), a
recent 10-year systematic review comparing insulin
initiation with continuation of OAD therapy found
earlier initiation of insulin therapy was associated
with greater reductions in A1C levels from baseline.5
The authors proposed a “paradigm shift” in clinical118practice toward early initiation of insulin in patients
with T2DM. Indeed, the feasibility of initiating insulin
and OAD therapy at diagnosis of T2DM was assessed
in a small-scale study (n ¼ 58).34 Patients treated with
ﬁrst-line insulin-based therapy showed no greater
weight gain or hypoglycemia and no decreased com-
pliance, treatment satisfaction, or quality of life
compared with patients treated with conventional 3
OAD therapy.
Some studies have explored the economic beneﬁts
of insulin initiation in patients with T2DM25,26,
29,32,35–38; however, to our knowledge there are no
studies directly addressing the economic outcomes of
early versus late initiation of insulin. In this study, we
show that, at baseline, there was a trend toward the
1 OAD and 2 OADs groups having higher costs
compared with the Z3 OADs group, except for
prescription costs, which were higher for the Z3
OADs group. After adding insulin to the treatment,
there was no overall difference between the groups
except for higher prescription costs and outpatient
visit costs for the Z3 OADs group. Although a
signiﬁcantly greater proportion of patients in the 1
OAD group had an all-cause hospital admission
compared with the 2 and Z3 OADs groups, there
was no signiﬁcant difference between the associated
inpatient and the overall all-cause health care costs.
Therefore, our data suggest that early insulin initiation
has no impact on overall costs.
A recently published study sought to investigate
health care expenditure stratiﬁed by timing of insulin
initiation in older adults in a real-world setting.39 This
study, which also showed that early insulin initiation
was associated with signiﬁcantly greater reduction in
A1C (P o 0.001), suggested no signiﬁcant differences
in hypoglycemia events or health care costs associated
with insulin initiation time. This study did not
differentiate types of basal insulin or control for the
time from diagnosis to when insulin was initiated or
consider covariates such as obesity. Here, we
demonstrate that the degree of beneﬁt associated
with initiating insulin varied according to individual
patient characteristics, including BMI and previous
OAD regimen as well as time of initiation. A patient-
centered approach to treatment, as advocated in the
joint ADA/EASD guidelines,1 is supported by these
data.
As this study is based on real-world data from large
national US claims databases combined with EMRVolume 38 Number 1
P. Levin et al.data, it has richer information than EMR or claims
data alone. However, as this was a retrospective,
observational study, the data may be subject to
selection bias and confounding and do not establish
causality of the treatment on observed outcomes.
Also, as the analyses were conducted using health
care claims data generated mainly for billing purposes,
they were potentially subject to coding errors. The
time between baseline and ﬁnal measures may not
have been equal for all patients due to the time
windows used to deﬁne baseline A1C and ﬁnal A1C.
Persistence with therapy was estimated through phar-
macy claims data, which reﬂected prescriptions ﬁlled
that were not necessarily taken or consumed. The
analyses were based on data from a commercially and
Medicare-insured US population and limited to those
who had merged claims and EMR data, so they may
not be representative or generalizable to other pa-
tients. Timing of insulin initiation and the clinical
rationale behind the therapy choices may not be
accurately reﬂected in the study because information
on the duration of diabetes was available only in a
subset of patients and the number of OADs served as
a proxy for the timing of insulin initiation relative to
disease progression. This study included patients who
initiated basal insulin between July 2004 and Decem-
ber 2010. In more recent years, however, the pattern
of antidiabetes drug use has changed, with less use of
sulfonylureas and thiazolidinediones and a greater use
of newer therapies.40 As such, this study may not be
reﬂective of patients receiving newer therapies.
CONCLUSIONS
Earlier initiation of basal insulin therapy in patients
with T2DM previously treated with 1 OAD resulted
in better clinical outcomes than adding insulin to
OAD treatment later in the course of therapy, with
no increase in overall costs. In this setting, the
intensiﬁcation of treatment with insulin as opposed
to sulfonylureas and thiazolidinediones could repre-
sent a clinical advantage for patients. The early insulin
use group has the lowest utilization of sulfonylureas
and lowest incidence of hypoglycemia at follow-up.
Non-severely obese patients appear to particularly
beneﬁt from earlier initiation of basal insulin therapy.
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